Pharmacokinetics of continuous infusion ceftolozane/tazobactam in two patients with extensive total body surface area burns

Documenti analoghi

• Pharmacokinetic and pharmacodynamic evaluation of sulbactam‐durlobactam in a critically ill patient on continuous venovenous hemofiltration infected with carbapenem‐resistant Acinetobacter baumannii‐calcoaceticus complex
  di: Wesley D. Kufel, et al.
  Pubblicazione: (2025)
• Pharmacokinetics of Sulbactam/Durlobactam in a Patient With Acute Renal Failure, Severe Obesity, and Carbapenem‐Resistant Acinetobacter baumannii Bacteremia: A Case Report
  di: Dan Ilges, et al.
  Pubblicazione: (2025)
• Current and emerging PCSK9‐directed therapies to reduce LDL‐C and ASCVD risk: A state‐of‐the‐art review
  di: Candice L. Garwood, et al.
  Pubblicazione: (2024)
• Response to comment on “International consensus recommendations for the use of prolonged‐infusion β‐lactams endorsed by the American College of Clinical Pharmacy (ACCP), the British Society for Antimicrobial Chemotherapy (BSAC), the Cystic Fibrosis Foundation (CFF), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), the Infectious Diseases Society of American (IDSA), the Society of Critical Care Medicine (SCCM), and the Society of Infectious Diseases Pharmacists”
  di: Lisa T. Hong, et al.
  Pubblicazione: (2024)
• Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis
  di: Susan E. Smith, et al.
  Pubblicazione: (2026)